This de-risking milestone increases the probability of a successful 510(k) submission in H2 2026. Traders should monitor for the actual submission filing and subsequent FDA clearance decision, which would open a large U.S. market. Given the $4M market cap, any positive FDA news could drive significant upside, but clearance is not guaranteed.
Price Chart
Executive Summary
Intelligent Bio Solutions announced it has resolved all cybersecurity and software review items for its upcoming FDA 510(k) submission, including 100% remediation of medium-risk vulnerabilities and full resolution of 19 SBOM vulnerabilities. The 510(k) package targeting codeine detection remains on track for H2 2026, reducing regulatory risk ahead of planned U.S. market entry into the multi-billion-dollar drug screening market.
Key Facts
- All cybersecurity review items addressed; 100% of medium-risk vulnerabilities remediated.
- Low-risk vulnerabilities reduced from 11 to 2, with risk-based justification for remaining items.
- All 19 software bill of materials (SBOM) vulnerabilities fully resolved.
- Independent third-party verification confirmed no remaining issues.
- 510(k) submission on track for calendar H2 2026, targeting codeine detection as initial indication.
- Manufacturing partnership with Syrma Johari MedTech expected to deliver >40% annual production cost savings and ~20 percentage point gross margin improvement.
Financial Impact
No financial data provided in filing. The U.S. drug screening market is described as multi-billion-dollar annual opportunity. Manufacturing partnership expected to reduce production costs by >40% and improve gross margins by ~20 percentage points post-clearance.
Risk Factors
- FDA 510(k) clearance is not guaranteed; the agency may request additional data or deny the application.
- Company has a $4M market cap and may require additional capital to fund U.S. commercial launch.
- Competition from established drug screening methods and other rapid testing technologies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (INBS) — Batch item 1 | 0001493152-26-034428 |
| Exhibit: ex99-1.htm | 0001493152-26-034428 |
| Document: 0001493152-26-034428-index-headers.html | 0001493152-26-034428 |
| Document: 0001493152-26-034428-index.html | 0001493152-26-034428 |
| Document: 0001493152-26-034428.txt | 0001493152-26-034428 |
| 8-K Filing (INBS) — Batch item 6 | 0001493152-26-034428 |
| Exhibit: ex99-1.htm | 0001493152-26-034428 |
| Document: 0001493152-26-034428-index-headers.html | 0001493152-26-034428 |
| Document: 0001493152-26-034428-index.html | 0001493152-26-034428 |
| Document: 0001493152-26-034428.txt | 0001493152-26-034428 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.64 (−2.67%) |
Oct 13, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $1.64 (+13.10%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.64 (+4.09%) |
Sep 15, 2026 5w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.64 (−16.75%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.64 (−20.77%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.64 (−26.79%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.64 (+28.70%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.64 (−38.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.64 (+38.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.64 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers